市場調査レポート

商品コード

1472312

肺気腫治療市場：治療タイプ別、タイプ別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Emphysema Treatment Market By Treatment Type (Medication, Oxygen Therapy, Surgery), By Type (Centriacinar, Panacinar, Others), By End User (Hospitals, Homecare, Specialty Centres, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2024年03月01日
発行: Allied Market Research
ページ情報: 英文 310 Pages
納期: 2～3営業日

価格

PDF (Business License)

USD 5,820 843,376円

レポートPDFを1名がご利用いただけるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は5回まで可能です。 2名以上でご利用の場合、追加料金を支払う事によりユーザーを最大５名まで追加する事が可能です。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,870 1,430,261円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.91円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の肺気腫治療市場は2022年に63億米ドルと評価され、2023～2032年にかけてCAGR 3.3％で成長し、2032年には87億米ドルに達すると予測されています。

肺気腫は、肺の気嚢（肺胞）の損傷を特徴とする慢性疾患で、呼吸困難につながります。この損傷は、刺激物、特にタバコの煙に長期間さらされることによって引き起こされます。気嚢の繊細な壁が損傷を受けると弾力性が失われ、肺からうまく息を吐き出せなくなります。その結果、肺に空気がこもって肺が膨らみ、息切れ、咳、喘鳴、その他の呼吸器症状を引き起こします。肺気腫の治療は、主に症状の管理と肺のさらなる損傷の予防に重点を置きます。気道周囲の筋肉を弛緩させ、気流を改善する気管支拡大薬などの薬剤が一般的に処方されます。重症例では、肺の炎症を抑えるためにコルチコステロイドが使用されます。血中酸素濃度が低い場合は酸素療法が必要になることもあります。進行すると、肺気腫による呼吸の問題が深刻な患者には、肺容量減少手術や肺移植などの外科的選択肢が検討されます。

世界の肺気腫治療市場の成長は、肺気腫の罹患率の上昇と世界の喫煙者数の急増によって牽引されると予想されます。肺気腫は、高齢者人口の急増、環境汚染の憂慮すべき増加、世界の喫煙の有病率の増加により、世界中でますます流行しています。例えば、米国国立医療図書館が発表した2022年の論文によると、米国における肺気腫の有病率は約1,400万人であり、米国を代表するCOPD疾患です。

さらに、大気汚染、工業排出物、有害粒子状物質への暴露などの環境要因が、特に汚染レベルが高い傾向にある都市部において、肺気腫発症のリスクをエスカレートさせています。世界の肺気腫の発生率の上昇は、この慢性疾患を管理するための効果的な治療介入の急増をもたらし、これが世界の肺気腫治療市場の成長を押し上げると予想されます。

さらに、世界の喫煙者数の増加が肺気腫治療市場の主要な推進力として浮上しています。例えば、世界保健機関（WHO）の2021年版によると、世界人口の22.3％がタバコを使用しており、130万人のタバコ喫煙者が低・中所得国に居住しています。世界中で喫煙習慣を持つ人が増加するにつれて、肺気腫の発生率も同時に上昇しています。喫煙は肺機能の悪化を進行させ、既存の呼吸器疾患を悪化させるため、肺気腫発症の主要な危険因子として広く認識されています。その結果、喫煙者数の増加は、肺気腫に関連する症状を管理し、患者のQOLを改善するための効果的な治療に対する需要の高まりにつながっています。したがって、世界の喫煙者数の増加が市場の成長を促進すると予想されます。

世界の肺気腫治療市場は、治療タイプ、種類、エンドユーザー、地域に区分されます。治療タイプ別では、市場は薬剤療法、酸素療法、手術に分けられます。タイプ別では、セントリアシナール、パナシナール、その他に分別されます。エンドユーザー別では、病院、在宅医療、専門センター、その他に分類されます。地域別では、北米地域（米国、カナダ、メキシコ）、欧州地域（フランス、ドイツ、イタリア、スペイン、英国、その他の欧州地域）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、その他のアジア太平洋）、南米地域（ブラジル、アフリカ、アラビア、その他のアジア太平洋）で分析されます。

利害関係者にとっての主要メリット

当レポートでは、2022～2032年までの肺気腫治療市場分析の市場セグメント、現在の動向、推定・動態の定量的分析を提供し、肺気腫治療市場の有力な機会を特定します。
市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を記載しています。
ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
肺気腫治療市場のセグメンテーションの詳細な分析により、市場機会を見極めることができます。
各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
市場参入企業のポジショニングはベンチマーキングを容易にし、市場参入企業の現在のポジションの明確な理解を記載しています。
地域別と世界の肺気腫治療市場動向、主要企業、市場セグメント、用途セグメント、市場成長戦略などの分析を含みます。

本レポートで可能なレポートカスタマイズ（追加費用とスケジュールがあります。）

国、地域、世界レベルでの患者/疫学データ
規制ガイドライン
クライアントの関心に応じた追加企業プロファイル
国別または地域別の追加分析-市場規模と予測
企業プロファイルの拡大リスト
過去の市場データ
SWOT分析

市場の定義と範囲
主要調査結果
- 影響要因
- 主要投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 肺気腫患者の増加
  - 世界の喫煙者数の急増
  - 肺気腫の原因となる大気汚染の増加
- 抑制要因
  - 高額な治療費
  - 薬剤に伴う副作用
- 機会
  - 新興市場における成長機会

第4章肺気腫治療市場：治療タイプ別

概要
薬剤療法
- 薬剤療法による肺気腫治療市場：タイプ別
酸素療法
外科療法

第5章肺気腫治療市場：タイプ別

概要
セントリアシナール
パナシナール
その他

第6章肺気腫治療市場：エンドユーザー別

概要
病院
在宅医療
専門センター
その他

第7章肺気腫治療市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第8章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline Plc.
Viatris Inc.
Novartis AG
Orion Corporation
Teva Pharmaceutical Industries Ltd.
Verona Pharma Plc.
Koninklijke Philips N.V.
Inogen, Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 02. EMPHYSEMA TREATMENT MARKET FOR MEDICATION, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL MEDICATION EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. EMPHYSEMA TREATMENT MARKET FOR OXYGEN THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 05. EMPHYSEMA TREATMENT MARKET FOR SURGERY, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 07. EMPHYSEMA TREATMENT MARKET FOR CENTRIACINAR, BY REGION, 2022-2032 ($MILLION)
TABLE 08. EMPHYSEMA TREATMENT MARKET FOR PANACINAR, BY REGION, 2022-2032 ($MILLION)
TABLE 09. EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 11. EMPHYSEMA TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. EMPHYSEMA TREATMENT MARKET FOR HOMECARE, BY REGION, 2022-2032 ($MILLION)
TABLE 13. EMPHYSEMA TREATMENT MARKET FOR SPECIALTY CENTRES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. EMPHYSEMA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 22. U.S. EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. CANADA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 25. CANADA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. MEXICO EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 28. MEXICO EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. EUROPE EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. EUROPE EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. GERMANY EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. FRANCE EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 38. FRANCE EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. UK EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 41. UK EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. ITALY EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. ITALY EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. SPAIN EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. SPAIN EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. JAPAN EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 57. JAPAN EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. CHINA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. CHINA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. INDIA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LAMEA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 75. LAMEA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 76. LAMEA EMPHYSEMA TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 79. BRAZIL EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. ASTRAZENECA: KEY EXECUTIVES
TABLE 90. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 91. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 92. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 93. ASTRAZENECA: KEY STRATERGIES
TABLE 94. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 95. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 96. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 97. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 98. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 99. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 100. GLAXOSMITHKLINE PLC.: PRODUCT SEGMENTS
TABLE 101. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 102. GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 103. VIATRIS INC.: KEY EXECUTIVES
TABLE 104. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 105. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 107. VIATRIS INC.: KEY STRATERGIES
TABLE 108. NOVARTIS AG: KEY EXECUTIVES
TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 110. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 111. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 112. ORION CORPORATION: KEY EXECUTIVES
TABLE 113. ORION CORPORATION: COMPANY SNAPSHOT
TABLE 114. ORION CORPORATION: PRODUCT SEGMENTS
TABLE 115. ORION CORPORATION: PRODUCT PORTFOLIO
TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 121. VERONA PHARMA PLC.: KEY EXECUTIVES
TABLE 122. VERONA PHARMA PLC.: COMPANY SNAPSHOT
TABLE 123. VERONA PHARMA PLC.: PRODUCT SEGMENTS
TABLE 124. VERONA PHARMA PLC.: PRODUCT PORTFOLIO
TABLE 125. VERONA PHARMA PLC.: KEY STRATERGIES
TABLE 126. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
TABLE 127. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
TABLE 128. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
TABLE 129. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
TABLE 130. INOGEN, INC.: KEY EXECUTIVES
TABLE 131. INOGEN, INC.: COMPANY SNAPSHOT
TABLE 132. INOGEN, INC.: PRODUCT SEGMENTS
TABLE 133. INOGEN, INC.: PRODUCT PORTFOLIO
TABLE 134. INOGEN, INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. EMPHYSEMA TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF EMPHYSEMA TREATMENT MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN EMPHYSEMA TREATMENT MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN EMPHYSEMA TREATMENT MARKET (2023-2032)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR MEDICATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR OXYGEN THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR SURGERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. EMPHYSEMA TREATMENT MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR CENTRIACINAR, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR PANACINAR, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. EMPHYSEMA TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR HOMECARE, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR SPECIALTY CENTRES, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF EMPHYSEMA TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. EMPHYSEMA TREATMENT MARKET BY REGION, 2022 AND 2032(%)
FIGURE 25. U.S. EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 26. CANADA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 27. MEXICO EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 28. GERMANY EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 29. FRANCE EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 30. UK EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 31. ITALY EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 32. SPAIN EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 33. REST OF EUROPE EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 34. JAPAN EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 35. CHINA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 36. INDIA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 37. AUSTRALIA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 38. SOUTH KOREA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 40. BRAZIL EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 41. SAUDI ARABIA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 42. SOUTH AFRICA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 43. REST OF LAMEA EMPHYSEMA TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 44. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 48. COMPETITIVE DASHBOARD
FIGURE 49. COMPETITIVE HEATMAP: EMPHYSEMA TREATMENT MARKET
FIGURE 50. TOP PLAYER POSITIONING, 2022
FIGURE 51. ASTRAZENECA: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 52. ASTRAZENECA: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. GLAXOSMITHKLINE PLC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 57. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 58. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 59. VIATRIS INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 60. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 61. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 63. ORION CORPORATION: NET SALES, 2021-2023 ($MILLION)
FIGURE 64. ORION CORPORATION: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 67. VERONA PHARMA PLC.: NET SALES, 2021-2022 ($MILLION)
FIGURE 68. KONINKLIJKE PHILIPS N.V.: NET SALES, 2021-2023 ($MILLION)
FIGURE 69. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY SEGMENT, 2023 (%)
FIGURE 70. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE BY REGION, 2023 (%)
FIGURE 71. INOGEN, INC.: NET REVENUE, 2021-2023 ($MILLION)
FIGURE 72. INOGEN, INC.: REVENUE SHARE BY REGION, 2023 (%)

Product Code: A14372

The global emphysema treatment market was valued at $6.3 billion in 2022, and is projected to reach $8.7 billion by 2032, growing at a CAGR of 3.3% from 2023 to 2032.

Emphysema is a chronic condition characterized by damage to the air sacs (alveoli) in the lungs, leading to difficulty in breathing. This damage is caused by long-term exposure to irritants, most commonly cigarette smoke. When the delicate walls of the air sacs are damaged, they lose their elasticity, making it difficult for the lungs to exhale properly. As a result, air is trapped in the lungs, causing them to inflate and leading to shortness of breath, coughing, wheezing, and other respiratory symptoms. Treatment for emphysema focuses primarily on managing symptoms and preventing further lung damage. Medications such as bronchodilators, which help to relax the muscles around the airways and improve airflow, are commonly prescribed. In more severe cases, corticosteroids are used to reduce inflammation in the lungs. Oxygen therapy may be necessary for those with low blood oxygen levels. In advanced stages, surgical options like lung volume reduction surgery or lung transplantation is considered for patients with severe breathing issues due to emphysema .

The growth of the global emphysema treatment market is expected to be driven by rise in incidence of emphysema and surge in number of smokers globally. Emphysema has been increasingly prevalent across the globe due to surge in geriatric population, alarming rise in environmental pollution, and increase in prevalence of smoking worldwide. For instance, according to 2022 article published by the National Library of Medicine, the prevalence of emphysema in the U.S. is approximately 14 million and is leading COPD disorder across the U.S.

In addition, environmental factors such as air pollution, industrial emissions, and exposure to harmful particulate matter have escalated the risk of developing emphysema, especially in urban areas where pollution levels tend to be higher. The rise in incidence of emphysema globally has resulted in surge in effective therapeutic interventions to manage this chronic disease, which is expected to boost the growth of the global emphysema treatment market.

Furthermore, increase in the number of smokers globally has emerged as a key driving force of the emphysema treatment market. For instance, according to the World Health Organization (WHO) 2021, 22.3% world's population use tobacco with 1.3 million tobacco smokers residing in low- and middle-income countries. With increasing number of individuals adopting smoking habits worldwide, the incidence of emphysema has escalated simultaneously. Smoking is widely recognized as the primary risk factor for developing emphysema, as it leads to the progressive deterioration of lung function and exacerbates existing respiratory conditions. Consequently, the escalating number of smokers has contributed to a heightened demand for effective treatments to manage emphysema-related symptoms and improve patients' quality of life. Thus, rise in number of smokers globally is expected to drive the growth of the market.

The global emphysema treatment market is segmented into treatment type, type, end user, and region. By treatment type, the market is divided into medication, oxygen therapy, and surgery. Depending on type, it is segregated into centriacinar, panacinar, and others. On the basis of end user, it is classified into hospitals, home care, specialty centers, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Novartis AG, Orion Corporation, Viatris Inc., Inogen, Teva Pharmaceuticals, Koninklijke Philips N.V., and Verona Pharma.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2022 to 2032 to identify the prevailing emphysema treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By End User

Hospitals
Homecare
Specialty Centres
Others

By Treatment Type

Medication
- Type
- Bronchodilators
- Steroids
- Others
Oxygen Therapy
Surgery

By Type

Centriacinar
Panacinar
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Viatris Inc.
Koninklijke Philips N.V.
GlaxoSmithKline Plc.
AstraZeneca
Novartis AG
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Inogen, Inc.
Orion Corporation
Verona Pharma Plc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of emphysema cases.
  - 3.4.1.2. Surge in number of smokers globally.
  - 3.4.1.3. Increase in air pollution contributing to emphysema.
- 3.4.2. Restraints
  - 3.4.2.1. High cost of treatment.
  - 3.4.2.2. Side effects associated with medications.
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunities in emerging markets.

CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Medication
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Medication Emphysema Treatment Market by Type
4.3. Oxygen Therapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Surgery
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Centriacinar
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Panacinar
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Homecare
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Specialty Centres
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country

CHAPTER 7: EMPHYSEMA TREATMENT MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Treatment Type
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Treatment Type
  - 7.2.5.1.2. Market size and forecast, by Type
  - 7.2.5.1.3. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Treatment Type
  - 7.2.5.2.2. Market size and forecast, by Type
  - 7.2.5.2.3. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Treatment Type
  - 7.2.5.3.2. Market size and forecast, by Type
  - 7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Treatment Type
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Treatment Type
  - 7.3.5.1.2. Market size and forecast, by Type
  - 7.3.5.1.3. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Treatment Type
  - 7.3.5.2.2. Market size and forecast, by Type
  - 7.3.5.2.3. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Treatment Type
  - 7.3.5.3.2. Market size and forecast, by Type
  - 7.3.5.3.3. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Treatment Type
  - 7.3.5.4.2. Market size and forecast, by Type
  - 7.3.5.4.3. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Treatment Type
  - 7.3.5.5.2. Market size and forecast, by Type
  - 7.3.5.5.3. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Treatment Type
  - 7.3.5.6.2. Market size and forecast, by Type
  - 7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Treatment Type
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Treatment Type
  - 7.4.5.1.2. Market size and forecast, by Type
  - 7.4.5.1.3. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Treatment Type
  - 7.4.5.2.2. Market size and forecast, by Type
  - 7.4.5.2.3. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Treatment Type
  - 7.4.5.3.2. Market size and forecast, by Type
  - 7.4.5.3.3. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Treatment Type
  - 7.4.5.4.2. Market size and forecast, by Type
  - 7.4.5.4.3. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Treatment Type
  - 7.4.5.5.2. Market size and forecast, by Type
  - 7.4.5.5.3. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Treatment Type
  - 7.4.5.6.2. Market size and forecast, by Type
  - 7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Treatment Type
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Treatment Type
  - 7.5.5.1.2. Market size and forecast, by Type
  - 7.5.5.1.3. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Treatment Type
  - 7.5.5.2.2. Market size and forecast, by Type
  - 7.5.5.2.3. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Treatment Type
  - 7.5.5.3.2. Market size and forecast, by Type
  - 7.5.5.3.3. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Treatment Type
  - 7.5.5.4.2. Market size and forecast, by Type
  - 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. AstraZeneca
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Boehringer Ingelheim International GmbH
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. GlaxoSmithKline Plc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Viatris Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Novartis AG
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Orion Corporation
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Teva Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Verona Pharma Plc.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Koninklijke Philips N.V.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Inogen, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

肺気腫治療市場：治療タイプ別、タイプ別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Emphysema Treatment Market By Treatment Type (Medication, Oxygen Therapy, Surgery), By Type (Centriacinar, Panacinar, Others), By End User (Hospitals, Homecare, Specialty Centres, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主要メリット

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章肺気腫治療市場：治療タイプ別

第5章肺気腫治療市場：タイプ別

第6章肺気腫治療市場：エンドユーザー別

第7章肺気腫治療市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By End User

By Treatment Type

By Type

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE

CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY TYPE

CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY END USER

CHAPTER 7: EMPHYSEMA TREATMENT MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

肺気腫治療市場：治療タイプ別、タイプ別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Emphysema Treatment Market By Treatment Type (Medication, Oxygen Therapy, Surgery), By Type (Centriacinar, Panacinar, Others), By End User (Hospitals, Homecare, Specialty Centres, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

利害関係者にとっての主要メリット

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 肺気腫治療市場：治療タイプ別

第5章 肺気腫治療市場：タイプ別

第6章 肺気腫治療市場：エンドユーザー別

第7章 肺気腫治療市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By End User

By Treatment Type

By Type

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: EMPHYSEMA TREATMENT MARKET, BY TREATMENT TYPE

CHAPTER 5: EMPHYSEMA TREATMENT MARKET, BY TYPE

CHAPTER 6: EMPHYSEMA TREATMENT MARKET, BY END USER

CHAPTER 7: EMPHYSEMA TREATMENT MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章肺気腫治療市場：治療タイプ別

第5章肺気腫治療市場：タイプ別

第6章肺気腫治療市場：エンドユーザー別

第7章肺気腫治療市場：地域別

第8章競争情勢

第9章企業プロファイル